Related Experiment Video

Updated: Feb 2, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.4K

Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma

Greta Del Mistro1,2, Philippe Lucarelli3, Ines Müller1,2

  • 11Experimental Dermatology, Department of Dermatology, TU-Dresden, Dresden, 01307 Germany.

NPJ Systems Biology and Applications
|November 13, 2018
PubMed

Insights

The novel drug IZI1551 effectively induces cell death in BRAF-mutant melanoma. Resistance is mediated by NFκB activation and XIAP upregulation, identified using advanced network modeling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Systems Biology

Background:

  • Metastatic melanoma poses a significant threat due to acquired resistance to targeted therapies.
  • Tumorigenic capacity can be regained through resistance mechanisms, limiting treatment efficacy.

Purpose of the Study:

  • To evaluate the efficacy of the novel TRAIL receptor-targeted agonist, IZI1551, in BRAF-mutant melanoma.
  • To identify molecular mechanisms underlying resistance to IZI1551 treatment.

Main Methods:

  • Utilized Dynamic Bayesian Network (DBN) modeling combined with a regularization strategy for network optimization.
  • Analyzed signaling networks in IZI1551-sensitive versus IZI1551-resistant melanoma cells.

Main Results:

  • IZI1551 demonstrated significant apoptotic cell death induction in BRAF-mutant melanoma cells.
  • The developed DBN model accurately predicted NFκB activation and XIAP upregulation as key resistance mediators.
  • Identified NFκB and XIAP as critical factors conferring resistance to IZI1551.

Conclusions:

  • IZI1551 shows promise as a therapeutic agent for metastatic melanoma.
  • Network modeling with regularization effectively identifies resistance mechanisms.
  • This approach may guide the development of combination therapies and patient stratification.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Related Concept Videos

Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.5K
Mutations01:39

Mutations

Overview
94.5K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.3K